Company: ARMP
Filing Date: 2025-12-01
Form Type: 424B5
Source: 0001104659-25-117382
Chunk: 10

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-12-01
Form: 424B5
Chunk 10
---
 from the two completed
Phase 2 studies position us to define a safe and promising biologic correlation for a Phase 3 definitive trial to evaluate inhaled AP-PA02
as an alternative to antibiotics in chronic pulmonary P. aeruginosainfection.

Contingent upon securing sufficient additional
funding, we may at the appropriate time in the future resume clinical development of AP-PA02 for NCFB, which may include the execution
of a definitive Phase 3 clinical trial. We are also actively exploring potential strategic partnerships as a means to further advance
this important program.

Additional Clinical Indications for AP-PA02

The current Pseudomonas phage
cocktail formulated for inhalation (AP-PA02) is prepared with the same high potency and purity of our injectable phage cocktail for Staphylococcus aureus (“S. aureus”) (AP-SA02). Based on the AP-SA02 clinical findings, we are exploring the potential development
of our Pseudomonas phage cocktail for acute ventilator-associated pneumonia and severe infections due to multidrug-resistant P. aeruginosa.

Staphylococcus aureusPhage Product Candidate, AP-SA02

Clinical Development of AP-SA02 in Bacteremia: Completed Phase 1b/2a Study

In parallel to developing novel phage therapeutics
that target chronic bacterial infections, we have an acute bacterial infection clinical development plan focused on S. aureusbacteremia,
a difficult-to-treat and often life-threatening human infection that can result in high morbidity and mortality and for which bacterial
resistance to antibiotics is growing.

We believe a key advantage of our phage manufacturing
expertise is the purity profiles of our phage products, including AP-SA02, our phage product candidate for S. aureus; this
has enabled us to pursue treatment of complicated S. aureus bacteremia, where repetitive intravenous (“IV”)
dosing is required.

On November 17, 2021, we announced that we
had received approval from the FDA to proceed with our IND application for AP-SA02.

On May 19, 2025, we announced positive topline data from the Phase 1b/2a diSArm study of intravenously administered AP-SA02 in complicated S. aureusbacteremia.The diSArm study (NCT05184764) was a Phase 1b/2a, multicenter, randomized, double-blind, placebo-controlled,
multiple